← Back to Search

Radiation Therapy

GRID Therapy for Sarcoma

N/A

Recruiting

Led By Theodore K Yanagihara, MD. PhD

Research Sponsored by UNC Lineberger Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age ≥ 18 years at the time of consent.

Eastern Cooperative Oncology Group (ECOG) Performance status of 0 - 2 (Karnofsky Performance Status equivalent of 50 - 100).

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months to 6 months

Awards & highlights

Study Summary

This trial is testing if GRID radiation therapy can safely increase the radiation dose in patients w/ extremity soft tissue sarcoma, potentially reducing recurrence rate w/o causing more post-op wound complications.

Who is the study for?

This trial is for adults over 18 with extremity soft tissue sarcoma, who can perform daily activities (ECOG status 0-2). They must have a biopsy confirming the diagnosis and agree to study procedures. Excluded are those with prior radiotherapy at the tumor site, complete tumor resection, serious wounds or bone fractures in the limb within 5 years, significant lymphedema, or certain autoimmune diseases.Check my eligibility

What is being tested?

The trial tests GRID therapy—a radiation technique that may increase dose without added toxicity—on patients with high-risk sarcoma before standard radiotherapy and surgery. The goal is to see if GRID improves tumor response without increasing wound complications after surgery.See study design

What are the potential side effects?

While specific side effects of GRID therapy will be studied, potential risks may include skin reactions similar to sunburns, fatigue from radiation treatment, and possible delayed wound healing post-surgery due to increased radiation exposure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I can take care of myself but may not be able to do heavy physical work.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months to 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months to 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Grade 2 or higher post-operative wound complications after GRID-3 months

Secondary outcome measures

Grade 2 or higher post-operative wound complications after GRID-6 months

Long Term Safety

The comparative effect of GRID

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Fractionated grid radiation therapyExperimental Treatment1 Intervention

Subjects with resectable extremity soft tissue sarcoma received neoadjuvant grid radiation therapy (GRID), followed by standard-of-care conventional radiotherapy (XRT) and tumor resection.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

UNC Lineberger Comprehensive Cancer CenterLead Sponsor

351 Previous Clinical Trials

88,313 Total Patients Enrolled

4 Trials studying Sarcoma

347 Patients Enrolled for Sarcoma

Theodore K Yanagihara, MD. PhDPrincipal InvestigatorUNC Lineberger Comprehensive Cancer Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this clinical research program still accept participants?

"The information on clinicaltrials.gov verifies that this trial is not currently looking to include participants, as the last update was registered in October 5th 2023. Although recruitment has officially ceased, there are a total of 452 studies still accepting patients at present time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

GRID Therapy for Extremity Soft Tissue Sarcoma

2023. "GRID Therapy for Extremity Soft Tissue Sarcoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06073067.

All > Surgery > Soft Tissue Sarcoma